262
Participants
Start Date
October 1, 2024
Primary Completion Date
August 8, 2025
Study Completion Date
December 8, 2025
AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Placebo comparator
Placebo matching IMP dose injected subcutaneously, once a week.
Research Site, Maroubra
Research Site, Merewether
Research Site, Heidelberg
Research Site, Maroochydore
Research Site, Lutherville-Timonium
Research Site, Statesville
Research Site, North Charleston
Research Site, Woodstock
Research Site, Orlando
Research Site, Hialeah
Research Site, Tampa
Research Site, Largo
Research Site, Mobile
Research Site, Knoxville
Research Site, Ridgeland
Research Site, Gulfport
Research Site, Indianapolis
Research Site, Kansas City
Research Site, Omaha
Research Site, Dallas
Research Site, Port Arthur
Research Site, San Antonio
Research Site, San Antonio
Research Site, Austin
Research Site, Phoenix
Research Site, Long Beach
Research Site, Portsmouth
Research Site, Hamilton
Research Site, Sarnia
Research Site, Stouffville
Research Site, Toronto
Research Site, Montreal
Research Site, Sherbrooke
Research Site, Chūōku
Research Site, Chūōku
Research Site, Shinjuku-ku
Research Site, Suita-shi
Research Site, Hull
Research Site, Leicester
Research Site, Penarth
Research Site, Rotherham
Lead Sponsor
AstraZeneca
INDUSTRY